Negative 2017 revenues for Germany-based Merck KGaA

Darmastadt-based chemical-pharmaceutical group Merck KGaA has reported today its 2017 financial results, which are below expectations, and shares (Frankfurt) have immediately declined by over 4%. The most severely hit arm in 2017 was Performance Materials, whose EBITDA dropped by 11% as compared to 2016 to €980m, due to  pressure on liquid crystals prices. Negative performances also came from the pharmaceutical division, especially from blockbusters Rebif (multiple sclerosis), Erbitux, (cancer) and Gonal-f , which lost significant market shares. On the positive side, unexpectedly good results came from the Consumer Health division–currently on sale–and from the laboratory tools division, which rose 5%.

(Source: Merck)